Systems biology and complex neurobehavioral traits.

There is evidence for a strong genetic component in the etiology of schizophrenia, as demonstrated by family, twin and adoption studies suggesting a heritability of about 80%. There are several approaches in the search for genetic risk factors such as linkage or association studies. Additionally, much effort was done in refining the phenotype including neuropsychology, neurophysiology, imaging or the generation of animal models. Genes becoming associated with schizophrenia have to be tested for functionality including e.g. metabolomics, transcriptomics, proteomics, generation of transgenic mice, analysis of protein-protein interactions, allele-specific RNA expression analysis, analysis of neuronal and stem cell cultures, as well as post mortem studies and behavioral studies in rodents. This amount of data requires complex data analysis. A system's perspective can help in the analysis of the structural and functional complexity of the brain. New tools will be needed for a more complex and systemic view. The systems biology approach could be a pivotal tool in understanding of complex behavior and diseases in future.

[1]  J A Frank,et al.  Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. , 2000, The American journal of psychiatry.

[2]  N. Andreasen.  Schizophrenia: the fundamental questions , 2000, Brain Research Reviews.

[3]  J. Waddington,et al.  Susceptibility genes for schizophrenia: Characterisation of mutant mouse models at the level of phenotypic behaviour , 2007, Neuroscience & Biobehavioral Reviews.

[4]  P. Sham,et al.  Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Harper,et al.  Translocation 5;21 and interstitial deletion of chromosome 7 in a case of chronic myelomonocytic leukemia. , 1988, Cancer genetics and cytogenetics.

[6]  C. R. Cloninger,et al.  The discovery of susceptibility genes for mental disorders , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  D. Rujescu,et al.  Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism , 2007, Schizophrenia Research.

[8]  R. Straub,et al.  Support for a possible schizophrenia vulnerability locus in region 5q22–31 in Irish families , 1997, Molecular Psychiatry.

[9]  Margot Albus,et al.  Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. , 2003, American journal of human genetics.

[10]  Nick Craddock,et al.  The genetic deconstruction of psychosis. , 2007, Schizophrenia bulletin.

[11]  Anil K Malhotra,et al.  Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.

[12]  F. Tretter,et al.  Schizophrenia, neurobiology and the methodology of systemic modeling. , 2006, Pharmacopsychiatry.

[13]  I. Gottesman,et al.  The endophenotype concept in psychiatry: etymology and strategic intentions. , 2003, The American journal of psychiatry.

[14]  Herbert Weingartner,et al.  NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.

[15]  P. Holmans,et al.  Multicenter linkage study of schizophrenia candidate regions on chromosomes 5q, 6q, 10p, and 13q: schizophrenia linkage collaborative group III. , 2000, American journal of human genetics.

[16]  M. Owen,et al.  An update on the genetics of schizophrenia , 2006, Current opinion in psychiatry.

[17]  H. Möller,et al.  Towards systemic theories in biological psychiatry. , 2006, Pharmacopsychiatry.

[18]  K. Lesch,et al.  When cells become depressed: focus on neural stem cells in novel treatment strategies against depression , 2002, Journal of Neural Transmission.

[19]  N Risch,et al.  The Future of Genetic Studies of Complex Human Diseases , 1996, Science.

[20]  R. Conley,et al.  Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. , 2000, The American journal of psychiatry.

[21]  Michael J Owen,et al.  Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? , 2005, Schizophrenia bulletin.

[22]  Marc G Caron,et al.  Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia , 1999, Cell.

[23]  H. Gurling,et al.  Exclusion of linkage to 5qll–13 in families with schizophrenia and other psychiatric disorders , 1989, Nature.

[24]  Minerva M. Carrasquillo,et al.  Genome-wide association study and mouse model identify interaction between RET and EDNRB pathways in Hirschsprung disease , 2002, Nature Genetics.

[25]  N. Andreasen,et al.  Understanding the causes of schizophrenia. , 1999, The New England journal of medicine.

[26]  R. Straub,et al.  A schizophrenia locus may be located in region 10p15-p11. , 1998, American journal of medical genetics.

[27]  W. Maier,et al.  Evidence suggestive of a locus on chromosome 5q31 contributing to susceptibility for schizophrenia in German and Israeli families by multipoint affected sib-pair linkage analysis , 1997, Molecular Psychiatry.

[28]  S. P. Fodor,et al.  Blocks of Limited Haplotype Diversity Revealed by High-Resolution Scanning of Human Chromosome 21 , 2001, Science.

[29]  D. Rujescu,et al.  Neurotoxicity of NMDA antagonists: a glutamatergic theory of schizophrenia based on selective impairment of local inhibitory feedback circuits , 2000, Dialogues in clinical neuroscience.

[30]  Lon R. Cardon,et al.  The complex interplay among factors that influence allelic association , 2004, Nature Reviews Genetics.

[31]  R. Murray,et al.  A combined analysis of D22S278 marker alleles in affected sib-pairs: support for a susceptibility locus for schizophrenia at chromosome 22q12. Schizophrenia Collaborative Linkage Group (Chromosome 22). , 1996, American journal of medical genetics.

[32]  M. Rietschel,et al.  Genetic models of schizophrenia and bipolar disorder , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[33]  W. Honer,et al.  Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. , 2000, Science.

[34]  R. Straub,et al.  Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. , 2002, American journal of human genetics.

[35]  R Kucherlapati,et al.  Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia , 2007, Molecular Psychiatry.

[36]  D. Weinberger.  Genetic mechanisms of psychosis: in vivo and postmortem genomics. , 2005, Clinical therapeutics.

[37]  R. Kahn,et al.  Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia , 2007, European Neuropsychopharmacology.

[38]  R. Murray,et al.  Suggestive evidence for linkage of schizophrenia to markers on chromosome 13q14.1‐q32 , 1995, Psychiatric genetics.

[39]  C. Stefanis,et al.  Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21 , 1998, Nature Genetics.

[40]  Aravinda Chakravarti,et al.  Nature, nurture and human disease , 2003, Nature.

[41]  J. Epplen,et al.  New genomic region for Wegener’s granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes , 2004, Human Genetics.

[42]  M. Owen.  Genomic approaches to schizophrenia. , 2005, Clinical therapeutics.

[43]  Jianxin Shi,et al.  No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. , 2008, The American journal of psychiatry.

[44]  Stefan Britsch,et al.  The neuregulin-I/ErbB signaling system in development and disease. , 2007, Advances in anatomy, embryology, and cell biology.

[45]  D. Lewis.  In pursuit of the pathogenesis and pathophysiology of schizophrenia: where do we stand? , 2002, American Journal of Psychiatry.

[46]  R. Fossdal,et al.  A whole genome association study in Icelandic multiple sclerosis patients with 4804 markers , 2003, Journal of Neuroimmunology.

[47]  H. Stefánsson,et al.  Neuregulin 1 and susceptibility to schizophrenia. , 2002, American journal of human genetics.

[48]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[49]  Leena Peltonen,et al.  Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. , 2003, American journal of human genetics.

[50]  Brien Riley,et al.  Molecular genetic studies of schizophrenia , 2006, European Journal of Human Genetics.

[51]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.